Volume 64, Issue 6, Pages 1428-1445 (June 2016) Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015  Johannes Wiegand, Florian van Bömmel, Andrés Duarte-Rojo, José Altamirano, Juan G. Abraldes, Augusto Villanueva, Thomas Berg  Journal of Hepatology  Volume 64, Issue 6, Pages 1428-1445 (June 2016) DOI: 10.1016/j.jhep.2016.02.020 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Characteristics of RG-101 (according to van der Ree, The Liver Meeting 2015). Journal of Hepatology 2016 64, 1428-1445DOI: (10.1016/j.jhep.2016.02.020) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Scheme of the HBV life cycle including targets for new drugs and new HBV biomarkers presented during the Liver Meeting 2015. Some antiviral drugs target the HBV life cycle as polymerase inhibitors (1), core assembly inhibitors (2), siRNAs (3) or at HBV secretion as nucleic acid polymers (4). A different approach is immune stimulation via TLR-7 or by therapeutic vaccine (5). Degradation of cccDNA is pursued based on the CRISPR/Cas9 system (6). New biomarkers being assessed for their clinical use include HBV RNA, of which the composition in serum is still under research, and HBV core related antigen, which binds to three different serum proteins of HBV (7). Journal of Hepatology 2016 64, 1428-1445DOI: (10.1016/j.jhep.2016.02.020) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions